Business, energy, technology, markets and global industry news from Business News Today

Yale School of Medicine

PharmaDeviceNews Yale School of Medicine
Infographic showing Urologic Design’s $1.2 million pre-seed financing for a patented urethral occlusion device, highlighting completed prototype and bench testing and plans for an initial human study in male stress urinary incontinence.
Medical Devices & Diagnostics

Urologic Design raises $1.2m to advance patented male incontinence device towards first human trial

Urologic Design has secured $1.2 million in pre-seed equity financing to advance a patented urethral occlusion device for men experiencing stress urinary incontinence. The company has completed prototype development and bench testing but must still establish safety, usability and effectiveness in its planned first human study.

Read More
Arcus Biosciences casdatifan data test whether next-generation HIF-2α inhibition can outperform late-line kidney cancer expectations
Pharma & Biotech

Estuary launches with $103m to develop gene therapies for polycystic kidney disease

Estuary Biotherapeutics has launched with $103 million in committed financing to develop kidney-targeted gene therapies for autosomal dominant polycystic kidney disease. Its two lead programmes target PKD2 and PKD1 mutations, building on mouse research suggesting that restoring polycystin activity can reverse some features of established kidney disease.

Read More
Newleos Therapeutics strengthens its neuroscience leadership by appointing former 89bio chief executive Rohan Palekar as board chairman while advancing its neuropsychiatry clinical pipeline. Representative image.
Pharma & Biotech

What Rohan Palekar’s appointment means for Newleos and its anxiety drug pipeline

Newleos names Rohan Palekar board chairman as three neuropsychiatry programs move through clinical proof-of-concept. Read the analysis.

Read More